Sep 13, 2023 / 09:50AM GMT
Graham Glyn Charles Parry - BofA Securities, Research Division - MD and Head of Healthcare Equity Research
To kick off. So welcome to the next session. I'm very pleased to be able to have from Sanofi with us today. Two different areas to talk about. So we'll probably try and split the timing roughly equally between the two. So we have Naimish Patel, who's the Therapeutic Area Head, for Immunology and Inflammation. And then François Sandre, who is the Head of Vaccines in Europe, so probably two the core pieces of Sanofi that we can get to discuss here. So welcome. Thanks for the time today.
Questions and Answers:
Graham Glyn Charles Parry - BofA Securities, Research Division - MD and Head of Healthcare Equity ResearchAnd I might kick off on the Immunology side with you, Naimish. So obviously, one of the biggest and best drivers of Sanofi at the moment is Dupixent across multiple different indications. So quite a tough act to follow if you're looking at developments. But perhaps you can just run through where you see where, particularly in atopic
Trustpilot
